VOLUME 22 NUMBER 10 OCTOBER 2015 nature structural & molecular biology a r t i c l e s microRNAs (miRs) are a class of small (~22-nt) genomically encoded molecules that inhibit translational initiation and stimulate decay of mRNA targets 1,2 . miRs are transcribed by RNA polymerase II and processed by the RNase III enzymes-Dicer and Drosha with its binding partner, DGCR8-to produce short double-stranded RNAs in the nucleus. One strand associates with the Argonaute (Ago) protein, thus forming the miR-mediated silencing complex (miRISC). miRs guide the pairing of miRISC, with imperfect complementarity, to sequences in target mRNAs, thus resulting in their subsequent destabilization and translational repression of the target 3 . The 'seed sequence' , at nucleotides 2-8, is a key determinant for miRISC-target recognition 4, 5 . Recent data have shown that 35-40% of miR-binding sites are found in 3′ untranslated regions (UTRs), 40-50% in coding regions and <5% in 5′-UTR regions of mRNAs 6, 7 . More than 60% of the human transcriptome has been predicted to be under miR regulation, thus making this post-transcriptional control pathway as important as protein pathways in the regulation of cell functions 2 . It is clear that miRs have essential roles in regulating diverse functions in normal and diseased cells 8, 9 .
a r t i c l e s microRNAs (miRs) are a class of small (~22-nt) genomically encoded molecules that inhibit translational initiation and stimulate decay of mRNA targets 1, 2 . miRs are transcribed by RNA polymerase II and processed by the RNase III enzymes-Dicer and Drosha with its binding partner, DGCR8-to produce short double-stranded RNAs in the nucleus. One strand associates with the Argonaute (Ago) protein, thus forming the miR-mediated silencing complex (miRISC). miRs guide the pairing of miRISC, with imperfect complementarity, to sequences in target mRNAs, thus resulting in their subsequent destabilization and translational repression of the target 3 . The 'seed sequence' , at nucleotides 2-8, is a key determinant for miRISC-target recognition 4, 5 . Recent data have shown that 35-40% of miR-binding sites are found in 3′ untranslated regions (UTRs), 40-50% in coding regions and <5% in 5′-UTR regions of mRNAs 6, 7 . More than 60% of the human transcriptome has been predicted to be under miR regulation, thus making this post-transcriptional control pathway as important as protein pathways in the regulation of cell functions 2 . It is clear that miRs have essential roles in regulating diverse functions in normal and diseased cells 8, 9 .
L1 belongs to the most abundant class of autonomous transposable elements 10 . Human L1 contains two open reading frames, ORF1 and ORF2, which encode a protein with RNA-binding and nucleotide acid-chaperone activity (ORF1) 11 and a protein with endonuclease and reverse-transcriptase activities (ORF2) [12] [13] [14] [15] , respectively. L1 mobilizes replicatively from one location in the genome to another by a 'copy-and-paste' mechanism, and it has been proposed to be a remnant of an ancient retrovirus 12, 16 . Active and inactive L1s have been implicated in the evolution of mammalian genomes and are linked to cell-based diseases, including cancer [17] [18] [19] . In addition, somatic L1 insertions are biased toward regions of cancer-specific DNA hypomethylation, thus suggesting that L1 insertions may provide a selective advantage during tumorigenesis 20 . Mechanisms that operate at different levels in gene-expression hierarchies have been selected to control transposition-mediated mutagenesis and mitigate the potential negative effects of newly inserted elements. In germ cells, a specific small-RNA subtype (piwi-interacting RNAs (piRNAs)) efficiently counteracts L1 activity, but these RNAs are not expressed in nongerm cells 21, 22 . Somatic cells attenuate element mobilization by DNA methylation of the L1 promoter 23 . Other methods of regulation are mediated by APOBEC proteins 24, 25 , microprocessor interactions 26 and Ago-mediated RNA interference in mouse embryonic stem cells 27 . L1-promoter silencing is greatly attenuated, and L1 transcription is reactivated in hypomethylated cells, such as cancer cells and tumor-initiating cells, and is also reactivated during reprogramming [28] [29] [30] . Because miRs act as regulators of gene expression and in antiviral defense mechanisms, we posited that they may also protect nongerm cells from encoded pathogenic assaults, such as L1 retrotransposition.
Here we show that miRs indeed bind directly to L1 ORF2 RNA, thus leading to decreases in full-length (FL) L1 RNA as well as de novo retrotransposition and integration events. Thus, we have uncovered a new mechanism in which miRs restrict L1 mobilization and L1-associated mutations in cancer cells, cancer-initiating cells and iPSCs.
RESULTS
iPSCs express elevated L1 ORF2 levels iPSCs and human embryonic stem cells (hESCs) are characterized by a global genomic hypomethylation state as well as the specific hypomethylation of the L1 promoter 28 . In order to assess L1 activity in iPSC lines, we first developed an efficient RNA-only (miR and mRNA) reprogramming strategy, as a means to obtain iPSCs from skin fibroblasts (RNA-iPSCs) (Fig. 1a) . In brief, RNA-iPSCs are reprogrammed from human skin fibroblasts by a single transfection of an miR cocktail (miR-200c, miR-302a-d and miR-369) 31 and subsequent daily transfections of mature mRNA transcripts encoding Klf4, Oct4, Sox2, c-Myc and Lin28 for 10-12 d, until the formation of mature iPSC colonies 32 (Fig. 1b) . The RNA-iPSCs express the cell-surface proteins TRA-1-60 and SSEA4 and the mRNAs of the transcriptionfactor genes POU5F1 (here denoted OCT4), NANOG, LIN28A, SOX2, DNMT3B, FOXD3 and TERT, which are associated with pluripotency, at abundance levels similar to those found in hESCs (H9 cells) and commercially available iPSC lines (IMR-90) (Fig. 1b-d) .
L1 activity in the generated iPSC lines (RNA-iPSCs) as well as IMR90, H9 and a teratoma cell line (Tera-1) was elevated, and all lines expressed L1 RNA at orders of magnitude higher than did parental skin (hBJ) cells (Fig. 1e) . These results support the conclusion that reprogramming by different methodologies renders cells vulnerable to genomic instability caused by retrotransposition.
Identification of retrotransposition-repressor miRs
We have shown previously that miRs can directly target hepatitis C viral RNA to repress viral replication 33 , thus raising the possibility that miRs could similarly repress L1 activity in hypomethylated somatic cells. Furthermore, depletion of three of the main proteins involved in miR biogenesis and miR function (Dicer, DGCR8 and Ago) in different cell types results in significantly increased L1 activity 26, 27 . To test whether miRs regulate L1 activity in somatic cells, we designed a lentiviral-based knockdown strategy in which libraries of expressed short hairpin RNAs (shRNAs) with anti-miR activity were used to neutralize endogenous miRs in HeLa cells. This approach favors a physiologically relevant response by avoiding potential artifacts resulting from ectopic overexpression occurring in miR-mimic library screens. We used a reporter construct encoding FL L1 mRNA and a luciferase retrotransposition-indicator cassette to identify miRs involved in repressing L1 activity 34 (Supplementary Data Set 1) . The luciferase protein can be translated into a functional enzyme only after retrotransposition of a spliced L1 transcript, thus allowing the quantification of cells with new retrotransposition events in culture 34 . We used a cotransfected Renilla reporter construct to normalize for potential differences in cell proliferation. Transient transfection of the reporter plasmids into the isolated shRNA anti-miRtransduced HeLa clones identified clones with significantly higher luciferase activity indicative of enhanced L1 retrotransposition activity (Fig. 2a) . Twice in independent clones, we identified a capacity of anti-miR-128 to derepress L1 activity at a significant level (Fig. 2a) . We verified that HeLa cells express miR-128 (Supplementary Fig. 1 ), and we validated the primary screen data by generating anti-miR-128 shRNA lentiviruses at high titer, transducing them into HeLa cells and then selecting with puromycin. We observed a highly significant a r t i c l e s npg a r t i c l e s increase in luciferase activity in cells expressing anti-miR-128 compared to cells expressing endogenous miR-128 (positive control) or cells that were not transduced with the reporter construct (negative control), thus indicating that the neutralization of miR-128 strongly derepressed L1 activity (Fig. 2b) . In addition, we characterized the effect of miR-128 neutralization by quantifying colony formation by essentially the same methodology with a transcription-and-translation cassette based on the neomycin-resistance gene (G418) 35 instead of the luciferase gene (Fig. 2c) . The colonyformation assay also is a functional assay reflecting the in vivo levels of retrotransposition and integration into the genome; neomycin resistance is conferred only by active retrotransposition and an integration event. We observed an ~200% increase in the number of neomycin-resistant colonies in cells with anti-miR-128 compared to HeLa cells with endogenous miR-128 levels (control), thus indicating higher rates of L1 activity and active retrotransposition in cells in which miR-128 is neutralized (Fig. 2c) . Last, we quantified the relative levels of L1 ORF2 RNA (in principle either genomic RNA or mRNA) by quantitative PCR (qPCR) analysis in cells stably transduced with anti-miR-128 compared to cells with endogenous miR-128 levels (positive control). To augment the low endogenous L1 levels, we transfected HeLa cells expressing anti-miR-128 or not with the L1 construct encoding FL L1 RNA, driven by the L1 native promoter (pWA355). We observed ~600% higher levels of L1 ORF2 RNA in cells expressing anti-miR-128 than in control cells that did not express anti-miR-128 (positive) or did not express the L1 transcript itself (negative), as normalized to β-2-microglobulin RNA levels (Fig. 2d) . These combined data support the conclusion that neutralization of endogenously expressed miR-128 results in increased L1 retrotransposition and integration activity. miR-128 is a specific modulator of L1 activity Although bioinformatics analyses failed to identify perfect seed matches in the 3′ UTR of L1 mRNA, they revealed a potential noncanonical miR-128 seed sequence in the coding region (ORF2) of L1 mRNA (Fig. 3a) . We determined the effects of miR-128 neutralization or overexpression on the levels of L1 transcript and retrotransposition activity by transducing HeLa cells with constructs expressing miR-128 mimics, anti-miR-128 shRNAs or control sequences. Because HeLa cells express low endogenous L1 activity, we transiently transfected a construct (pJM101/L1RP) encoding FL wild-type (WT) L1 under control of the highly active CMV promoter and monitored the effects of miR-128 or anti-miR-128 on L1 RNA. Stably transduced cells expressing anti-miR-128 exhibited significantly higher levels A2  A3  A4  A5  A6  A7  A8  A9  A10  A11  A12  B1  B2  B3  B4  B5  B6  B7  B8  B9  B10  B11  B12  C1  C2  C3  C4  C5  C6  C7  C8  C9  C10  C11  C12  D1  D2  D3  D4  D5  D6  D7  D8  D9  D10  D11  D12   E1  E2  E3  E4  E5  E6  E7  E8  E9  E10  E11  E12  F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F12  G1  G2  G3  G4  G5  G6  G7  G8  G9  G10  G11  G12  H1  H2  H3  H4  H5  H6  H7  H8  H9  H10  H11 a r t i c l e s of L1 RNA than control sequence, because endogenously expressed miR-128 levels were neutralized, and L1 RNA therefore was derepressed ( Fig. 3b) . Conversely, cells expressing miR-128, compared to controls, repressed L1 RNA expression (Fig. 3b) . To exclude the possibility that miR-128 overexpression above physiological levels may have led to secondary effects of lentiviral miR-128 modulation that could confound the results, we transfected anti-miR-128 oligonucleotides or synthetic miR-128 mimics into HeLa cells and determined L1 ORF2 RNA expression 48 h later. We observed significant derepression of L1 ORF2 RNA in cells transfected with antimiR-128 oligonucleotide ( Supplementary Fig. 2a ) and repression of L1 ORF2 RNA in cells transfected with the synthetic miR-128 mimic ( Supplementary Fig. 2a) . In addition, we tested the effect of miR-128 on FL L1 RNA by analyzing expression levels of the 5′ UTR and ORF1 of L1, in addition to ORF2, in HeLa cells stably transduced with miR-128, anti-miR-128 or control miRs. In cells in which miR-128 was overexpressed, levels of 5′-UTR, ORF1 and ORF2 RNA were significantly decreased ( Fig. 3d) , whereas cells in which miR-128 had been neutralized showed substantially higher 5′-UTR, ORF1 and ORF2 expression levels ( Fig. 3d) . To establish that miR-128 indeed regulates the full-length transcript, we performed semiquantitative reverse-transcription PCR (RT-PCR), analyzing the expression levels of the FL 6-kb L1 RNA in HeLa cells, in which L1 was introduced. Anti-miR-128 enhanced FL L1 RNA (Fig. 3e) , whereas miR-128, compared to a control miR, potently decreased FL L1 RNA expression levels ( Fig. 3e) . We verified that miR-modulated HeLa cells indeed overexpressed (miR-128) or expressed decreased levels of miR-128 (anti-miR-128) by performing miR-128-specific qPCR and analyzing effects on an additional downstream miR-128 target (Bmi1 (ref. 36)) ( Supplementary Fig. 3 ). In addition, we verified that the L1 plasmid was introduced into miR-expressing HeLa cells at equal levels, by quantifying levels of construct backbone (hygromycin) by qPCR and colony-formation assays ( Supplementary Fig. 4 ). L1 ORF1 protein levels also were higher in cells transfected with anti-miR-128 and were lower in cells transfected with miR-128, consistently with RNA abundance ( Fig. 3b-f) . Furthermore, cells transduced with anti-miR-128, compared to controls, exhibited a significantly higher number of neomycin-resistant colonies, and cells transduced with miR-128 had a significantly lower number of neomycin-resistant colonies, consistently with lower rates of retrotransposition (Fig. 3g) . These combined data support the conclusion that miR-128 induction or neutralization results in a corresponding decrease or increase, respectively, in L1 RNA, protein and retrotransposition, and they establish a role of miR-128 as a specific modulator of L1 activity. Tera-1 cells are derived from a testicular teratoma and have high endogenous levels of L1 activity 15 ( Fig. 1e and Supplementary Fig. 1 ). We used Tera-1 cells to provide a proof of principle regarding endogenous L1 regulation: we predicted that if we could use miR-128 to achieve significant reduction of L1 activity in a cell type with high L1 expression, then miR-128 would probably decrease L1 activity in other cancer (Fig. 3h) . Transient transfection of anti-miR-128 or miR-128 (Supplementary Fig. 2b ) and quantification of FL L1 RNA (Supplementary Fig. 2c ) confirmed these results. Furthermore, because tumor-initiating cells can drive tumor progression 37 , regulation of L1-induced mutagenesis of such cell types would be of importance. We found that transient transfection of colon cancer-initiating cells (CCICs) with miR-128 significantly reduced L1 RNA expression, whereas miR-128 neutralization by anti-miR-128 enhanced L1 RNA expression relative to that of controls (Fig. 3h) . In addition, we analyzed the effect of miR-128 on L1 activity in two additional tumor cell lines (non-small cell lung cancer cells (H23) and transformed human embryonic kidney cells (HEK293T)). As expected, miR-128 regulated L1 RNA expression in H23 and HEK293T cells in a similar manner as that observed for HeLa, Tera-1 and CCIC cells (Supplementary Fig. 2d ). In summary, these results support the conclusion that miR-128 is a specific modulator of induced as well as endogenous L1 RNA levels in cancer cells, teratoma cells and CCICs, and that miR-128 additionally regulates L1 ORF1 protein levels and de novo L1 retrotransposition and integration.
miR-128 represses L1 activity in iPSCs
Finally, we wished to test whether miR-128 could be used as a tool to decrease the high L1 activity, as determined by the high ORF2 expression levels observed in iPSCs (Fig. 1e) . miR-128 significantly decreased L1 ORF2 RNA expression in four different iPSC lines (reprogrammed with KOSM factors or RNA transfections) compared to parental control-miR iPSC lines (Fig. 4a) . In contrast, anti-miR-128 substantially enhanced L1 ORF2 RNA expression in all iPSC lines compared to parental control-miR iPSCs (Fig. 4a) . We verified endogenously expressed miR-128, as well as expression levels of miR-128 in miR-128-iPSCs and anti-miR-128-iPSCs as previously described (Supplementary Figs. 3-5) . We next tested the effect of miR-128 modulation on FL L1 RNA degradation in iPSCs, as determined by expression levels of the 5′ UTR, ORF1 and ORF2 by qPCR, and found that miR-128 significantly decreased the expression of FL L1 RNA (Fig. 4b) , whereas anti-miR-128 substantially increased the expression of FL L1 RNA (Fig. 4b) . In addition, miR-128 decreased L1 ORF1 protein expression, and anti-miR-128 increased ORF1 protein expression in iPSCs, as determined by immunoblot analysis (Fig. 4c) . Finally we wished to determine de novo retrotransposition events in iPSCs. To this end, we generated stable miR-128, anti-miR-128 and control-miR iPSC lines, into which we introduced the neomycin-resistance L1 reporter cassette and measured new retrotransposition and integration events of L1 in iPSCs. miR-128 significantly decreased retrotransposition and integration of L1 into the genome of iPSCs (Fig. 4d) , and neutralization of miR-128 strongly increased retrotransposition, as determined by colony-formation assays (Fig. 4d) . These results suggest that miR-128 is a specific regulator of endogenous L1 RNA levels, regulating L1 ORF1 protein levels and de novo retrotransposition and the integration of L1 into the genome of iPSCs.
miR-128 represses L1 activity by direct binding to L1 RNA miR-128 could potentially regulate L1 expression by directly interacting with L1 RNA, regulating expression of other proteins that regulate L1, or both. To address the possibility that miR-128 directly npg a r t i c l e s interacts with L1 RNA, we introduced a silent mutation into the putative miR-128-binding site in ORF2 of L1 RNA ( Supplementary  Fig. 6a ). Luciferase activity was significantly lower than that of controls in HeLa cells transfected with the WT L1 construct and mature miR-128, thus supporting the conclusion that miR-128 can bind to the WT L1 RNA sequence and prevent retrotransposition (Fig. 5a) . In contrast, HeLa cells transfected with the mutant L1 RNA-binding site and either mature miR-128 or control-miR mimics exhibited luciferase activity at the same levels as in the WT L1 and control-miR cells, consistently with miR-128 no longer binding and repressing reporter-gene expression. As expected, L1 RNA with a perfect match at the miR-128-binding site was strongly repressed by miR-128 (Fig. 5a) . To extend the analysis, we mutated the miR-128-binding site in the L1 construct used in Figure 3 to increase the levels of L1 RNA in HeLa cells. The WT L1 expression construct and that with a mutated miR-128-binding site were transfected into HeLa cells stably transduced with miR-128, anti-miR-128 shRNA or control miR. Consistently with previous results, anti-miR-128 derepressed L1 ORF2 RNA expression levels, and miR-128 repressed L1 ORF2 RNA expression levels when the WT L1 plasmid was transfected into HeLa cells (Fig. 5b) . In contrast, the construct with the mutated miR-128-binding site showed that expression of miR-128 or control miR failed to downregulate L1 ORF2 levels, thus supporting the conclusion that the introduced mutation at the miR-128-binding site abrogated interaction between miR-128 and the target site, thus resulting in higher levels of L1 RNA (Fig. 5b) .
The effect of the mutation of the miR-binding site on L1 retrotransposition activity also supported this conclusion: HeLa cells overexpressing miR-128 and the WT plasmid exhibited fewer neomycin-resistant colonies and lower retrotransposition relative to controls, as expected (Fig. 5c) . However, when the mutated plasmid was transfected into HeLa cells overexpressing miR-128, or control miR, significantly higher numbers of neomycin-resistant colonies formed (Fig. 5c) . Introduction of anti-miR-128, compared to controls, neutralized endogenously expressed miR-128 and enhanced L1 expression, as previously shown (Fig. 3b) . In a similar manner, induced miR-128 and endogenously expressed miR-128 were incapable of binding and repressing mutant L1, thus resulting in twofold-higher L1 expression levels than in controls. We verified the transfection and transduction efficiency of miR-modulated HeLa cells, as described previously (Supplementary Figs. 3 and 4) . Because miR-128 is unable to bind to mutated L1 ORF2 RNA and repress RNA active retrotransposition, these data support the conclusion that miR-128 represses L1 RNA retrotransposition and integration via a direct interaction with the target site on the ORF2 RNA. L1 RNA in miR-128 mutant-site cells is higher than in controls because miR-128 (overexpressed or endogenously expressed) cannot bind and repress mutant L1 RNA.
miR-128 interacts with L1 RNA
To directly test whether miR-128 binds to L1 RNA, we isolated Ago complexes containing miRs and target mRNAs by immunopurification from cells expressing miR-128 or anti-miR-128 and assessed relevant complex occupancy by L1 RNA. As expected, the relative level of total L1 RNA was lower in Tera-1 cells stably overexpressing miR-128 than in those expressing anti-miR-128 (Fig. 6a) . Despite the lower levels of L1 RNA, Ago-bound L1 RNA was significantly higher in cells overexpressing miR-128 than in cells in which miR-128 was downregulated by anti-miR-128 (Fig. 6b) . When we corrected for the higher levels of L1 ORF2 in Tera-1 cells treated with anti-miR-128, the difference in bound L1 RNA was even more significant (corrected anti-miR-128). These results provide direct evidence that miR-128 binds to L1 RNA. We repeated the Ago immunopurification experiments in HeLa cells stably transduced with anti-miR-128 or miR-128, which were transfected with L1 expression plasmids (encoding either WT L1 or L1 with a mutant miR-128-binding site). Overexpression of miR-128, compared to transduction with anti-miR-128, led to significantly lower levels of total WT L1 RNA, as observed previously (Fig. 6c) . Also as expected, the relative level of total mutant L1 RNA was higher than that of WT L1 RNA in cells transduced with miR-128. The relative level of total L1 RNA was lower in HeLa cells stably overexpressing miR-128 than in those expressing anti-miR-128 (Fig. 6c,d ). When we corrected for the higher levels of L1 ORF2 in HeLa cells treated with anti-miR-128, the difference was even more a r t i c l e s significant ( Fig. 6d ; corrected anti-miR-128). In addition, even though mutant L1 RNA was expressed at higher levels in cells transduced with miR-128 compared to WT L1, it immunopurified less efficiently than WT L1 RNA from miR-128-transduced cells (Fig. 6c,e) . When we corrected for the higher levels of L1 ORF2 in mutant-treated HeLa cells, the difference was even more significant ( Fig. 6e; corrected anti-miR-128 ). These results demonstrate that the putative miR-128-binding site in the ORF2 region of L1 RNA is indeed the functional binding site. A control, constitutively expressed transcript of the GAPDH gene did not show altered levels of total RNA in cells transduced with miR-128 or anti-miR-128, or relative differences in Ago immunopurification (Supplementary Fig. 2e ).
DISCUSSION
Our findings complement previous work on L1 post-transcriptional regulation by Caceres and colleagues 26, 38 , which identified multiple direct binding sites in the L1 5′ UTR for the microprocessorcomplex subunit DGCR8 (ref. 38) , which binds and cleaves L1 RNA 26 . Our results expand this work and suggest a scenario in which DGCR8 binds to double-stranded RNA structures of the 5′ UTR of L1 RNA and cleaves L1 in the nucleus; L1 transcripts that escape DGCR8-mediated control are transported out of the nucleus, where a second miR-mediated mechanism regulates their expression levels and represses their effects in the cytoplasm. It is possible that miR-128 also affects translational repression of L1 RNA and/or represses transcription of L1; however, our results indicate that RNA degradation is the main mechanism by which miR-128 represses L1 activity. Genomic alignment analysis of human, chimpanzee, rat and mouse sequences interestingly shows that the miR-128-binding site in L1 ORF2 is 100% conserved between humans and chimpanzees, and partly conserved (one or two mismatches) in mice and rats (Supplementary Fig. 6b) . From our findings, we propose that miRs (miR-128) have adopted part of piRNAs' role in nongerm cells 21 by binding directly to the ORF2 of L1 RNA, thus resulting in L1 repression and decreasing the risk of genomic instability. These results suggest that miRs, in addition to being key regulatory molecules, have evolved to protect somatic cells (including cancer cells, cancer-initiating cells and iPSCs) from pathogenic RNA molecules originating from extracellular sources, such as RNA viruses, or from intracellular encoded sources, such as retrotransposons, thereby taking on an important function as protectors of genomic stability (Fig. 6f) .
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Induced pluripotent stem-cell reprogramming. iPSCs were generated from human foreskin fibroblasts (early-passage hBJ, discontinued, Stemgent) with an mRNA Reprogramming Kit (00-0071, Stemgent) in combination with a micro-RNA Booster Kit (00-0073, Stemgent). The resultant iPSCs are termed RNA-iPSCs. hBJ cells were plated at a density of 5 × 10 4 cells per well of a six-well Matrigelcoated plate (354277, Corning) and incubated at 37 °C and 5% CO 2 for 24 h. The oxygen tension was then decreased from ambient to 5%, before the start of the transfection schedule. Throughout the protocol, medium was changed daily with Pluriton (00-0070, Stemgent) preconditioned with inactivated newborn human foreskin fibroblasts (GSC-3006G, GlobalStem) containing 300 ng/mL B18R (34-8185, eBiosciences) and 1× Pluriton supplement (stock 2,500×). All RNA transfections were carried out with a Stemfect Transfection Kit (00-0069, Stemgent). On day 0 of reprogramming, 70 pmol of miR cocktail was transfected into the hBJ cells. 37 . Briefly, CCICs were cultured as spheres in ultra-low attachment flasks in DMEM/F12, N2 supplement (17502-048, Life Technologies), B27 supplement (17504-044, Life Technologies), heparin (4 µg/mL, Sigma), epidermal growth factor (20 ng/mL), and basic fibroblast growth factor (20 ng/mL). H23 cells (CRL-5800, ATCC) were cultured in RPMI-1640 (11875, Life Technologies), 10% HI-FBS, 5% Glutamax, and 1% Normocin. All cells were cultured at 37 °C and 5% CO 2 and routinely checked for mycoplasma. Cell lines were not independently authenticated in our laboratory.
Derepression L1 anti-miR library screen. HeLa cells were transduced with miRZip Virus Library (MZIPPLVA, System Biosciences), selected with puromycin and split to single-cell dilutions. Luciferase reporter plasmids pWA355 (50 µg) as well as the normalization plasmid pGL4.74 (Renilla luciferase) were transfected with FuGENE HD (E2311, Promega), and results were read on a GloMax-multi reader (Promega) with the Dual-Glo Luciferase assay system (E2940, Promega).
RNA extraction and quantification of mRNAs. RNA was extracted with TRIzol, Zymogen Directzol, Qiagen RNeasy Kit or Qiagen miRNeasy Kit, according to the manufacturers' instructions. mRNA levels were analyzed by qPCR with TaqMan One
Step RT-PCR kit or SYBR Green (Life Technologies), relative to β-2-microglobulin (B2M), GAPDH or GUSB housekeeping genes and processed with the ∆∆C t method. miR-128 levels were determined by miScript II RT and primer qPCR assay (Qiagen); miR-128 levels were normalized to RNU5A with the ∆∆C t method. Immunoblotting. Rabbit anti-human L1 ORF1p, custom generated by Genscript and validated by ELISA, was used at 1:1,000. Anti-α-tubulin (ab4074, Abcam), used as a loading control, was diluted 1:5,000; validation can be found on the manufacturer's website. All uncropped immunoblots can be found in Supplementary Data Set 2. Colony-formation assay. Stable HeLa lines expressing miR-128, anti-miR-128 or scrambled control were transfected with pJM101/L1RP (containing a neomycinresistance retrotransposition-indicator cassette) per well with X-treme gene HP DNA transfection reagent (06366236001, Roche) according to the manufacturer's instructions. Cells were selected with 500 µg/mL G418 (ant-gn-1, Invivogen). Neomycin-resistant colonies were fixed with cold 1:1 methanol/acetone and then visualized with May-Grunwald (ES-3410, Fisher) and Jenner-Giemsa staining kits (ES-8150, Fisher) according to the manufacturer's protocol. Stable iPSC lines expressing miR-128, anti-miR-128 or scrambled control were transfected with pJM101/L1RP with Xtreme gene HP DNA transfection reagent according to the manufacturer's instructions. Selection began with 25 µg/mL G418 72 h after transfection and was maintained with daily medium changes until negative-control (nontransfected) cells had died. Neomycin-resistant colonies were prepared as described above.
RT-PCR.
Mutation of the miR-128-binding site. For the mutation of the potential miR-128-binding site in ORF-2 of the L1 reporter, the complete L1 reporter cassette was excised from the pJM101/L1RP plasmid by SalI digest. The fragment was purified by gel extraction and inserted into the SalI-digested backbone of pcDNA3.1. The resultant plasmid pL1-Neo-Reporter was drastically reduced in size, thus allowing for the construction of a mutated fragment by fusion PCR and insertion into the pL1-Neo-Reporter. For the fusion PCR, the primers (sequences in Supplementary Data Set 1) were used to amplify the fragments with the Phusion PCR polymerase system (NEB). For the fusion, 2 µl of the first PCR was used as a template for the generation of the long fragment, with PCRI primer sense and PCRII primer antisense, and amplified by standard PCR with the Phusion PCR polymerase system (NEB). The fusion fragment includes the mutated miR-128, and it was purified by gel electrophoresis. The original ORF-2 sequence was replaced in the pL1-Neo-Reporter by the fusion fragment, by cutting the plasmid and the fusion fragment with restriction enzymes AfeI and EcoRI, and was then ligated.
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